Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Aurinia Pharmaceuticals Inc. (AUPH) is a Biotechnology company based in CA with a market capitalization of $2B. Revenue grew 20.4% year-over-year and the company generated $135.4M in free cash flow. This page tracks AUPH's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
CA · 130 employees · IPO Sep 3, 2014
Valuation
Valuation & price
$15.16as of May 26, 2026· -18.6% vs 52w high
7.3
P/E ratio
Latest-FY diluted EPS
3.36
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$2B
Market cap
20.4%
Revenue growth (YoY)
88.5%
Gross margin
$135.4M
Free cash flow (USD)
-$323.2M
Net debt
Net cash position
-6.1%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
1
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 4, 2026Filing
Annual Meeting Results
- Insider buyJun 2, 2026Filing
Insider Buy $12.5MTANG KEVIN · Director, Chief Executive Officer, 10% Owner · $12.5M
- 8-K eventMay 11, 2026Filing
Acquisition Completed
- 8-K eventMay 7, 2026Filing
Earnings Release
- Quarterly reportMay 7, 2026Filing
10-Q Filed
- 8-K eventApr 3, 2026Filing
Merger Agreement
Questions
Frequently asked questions
What is Aurinia Pharmaceuticals Inc.'s market cap?
Aurinia Pharmaceuticals Inc. (AUPH) has a market capitalization of $2B.
What is AUPH's P/E ratio?
AUPH trades at a price-to-earnings ratio of 7.3, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is AUPH's price-to-book (P/B) ratio?
AUPH trades at 3.36 times book value per share.
Are insiders buying AUPH stock?
Yes — SEC Form 4 filings show 1 open-market insider buy and 0 sells at Aurinia Pharmaceuticals Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.